TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28177189
Drug: High cortisol
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High cortisol (c. 1400 nM) with low insulin
Study: 28177189
Drug: High cortisol
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High cortisol (c. 1400 nM) in vitro with insulin
Study: 28177189
Drug: High cortisol
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High cortisol (c. 1400 nM) in vitro without insulin
Study: 24124684
Drug: One-stop diagnosis
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One-stop diagnosis and treatment group (CTU 3-D reconstruction, ultrasound and radiology guided puncture followed by PCNL)
Study: 12212157
Drug: External irradiation
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: External irradiation and after-load intracavitary radiation in combination with traditional Chinese medicine (EIAIRC)
Study: 12212157
Drug: External irradiation
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: External irradiation plus traditional Chinese medicine (EIC)
Study: 8837569
Drug: No medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medication (ischemia-none group)
Study: 1450659
Drug: lodoxamide 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: lodoxamide 0.1% ophthalmic solution
Study: 1450659
Drug: sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: sodium cromoglycate 2% ophthalmic solution
Study: 6375407
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Doxycycline (DX)
Study: 23845740
Drug: Metformin (1700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1700 mg/die)
Study: 23845740
Drug: Metformin (1700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1700 mg/die) plus low-dose spironolactone (25 mg/die)
Study: 20148739
Drug: Metformin (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1500 mg)
Study: 20148739
Drug: Metformin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin + Lifestyle modification
Study: 9932655
Drug: 33 mmol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 33 mmol/L bicarbonate solution
Study: 9932655
Drug: 40 mmol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mmol/L lactate solution
Study: 7708260
Drug: Ultrafiltration rate
Normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrafiltration rate of 60 ml/min with dialysate calcium concentration of 1.63 mmol/l
Study: 7708260
Drug: Ultrafiltration rate
Normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrafiltration rate of 100 ml/min with dialysate calcium concentration of 1.63 mmol/l
Study: 7708260
Drug: Infusion rate
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion rate of 2.5 l/h with dialysate calcium concentration of 1.63 mmol/l
Study: 7708260
Drug: Infusion rate
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion rate of 5 l/h with dialysate calcium concentration of 1.63 mmol/l
Study: 7708260
Drug: Infusion rate
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion rate of 2.5 l/h with dialysate calcium concentration of 1.5 mmol/l
Study: 7708260
Drug: Infusion rate
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion rate of 5 l/h with dialysate calcium concentration of 1.5 mmol/l
Study: 7708260
Drug: Infusion rate
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion rate of 2.5 l/h with dialysate calcium concentration of 1.25 mmol/l
Study: 7708260
Drug: Infusion rate
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion rate of 5 l/h with dialysate calcium concentration of 1.25 mmol/l
Study: 2658462
Drug: Sodium hyaluronate
Normalized name: sodium hyaluronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium hyaluronate treatment (both concentrations)
Study: 30406819
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of amlodipine (10 mg/day) plus medium dose of ARB (high-AML)
Study: 30406819
Drug: Medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose of amlodipine (5 mg/day) plus high dose of ARB (high-ARB)
Study: 26073354
Drug: Linagliptin 2.5
Normalized name: linagliptin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linagliptin 2.5 mg/metformin 850 mg
Study: 26073354
Drug: Linagliptin 2.5
Normalized name: linagliptin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linagliptin 2.5 mg/metformin 500 mg
Study: 19534294
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH insulin (10U) injection into the carpal tunnel
Study: 17453298
Drug: Gemcitabine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1000 mg/m²) every 7 days for 43 days
Study: 17453298
Drug: Gemcitabine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1000 mg/m²) and cisplatin (25 mg/m²)
Study: 11452568
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment twice weekly for 8 weeks
Study: 11452568
Drug: Crossover control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossover control group receiving acupuncture treatments twice weekly for 8 weeks
Study: 2656774
Drug: Indomethacin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (75 mg daily for 3 days)
Study: 29665733
Drug: Methylprednisolone administration
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone administration
Study: 27681442
Drug: Lanicemine 50
Normalized name: Lanicemine
DrugBank: Lanicemine (DB11889)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanicemine 50 mg
Study: 27681442
Drug: Lanicemine 100
Normalized name: Lanicemine
DrugBank: Lanicemine (DB11889)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanicemine 100 mg
Study: 25412724
Drug: Peer-led HIV
Normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer-led HIV medication adherence intervention ('Ready')
Study: 22749633
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy plans compliant with SIOPEN protocol guidelines
Study: 22749633
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy plans with justifiable deviations
Study: 22749633
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy plans with justifiable deviations that might result in adverse effects
Study: 22749633
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy plans with unjustified deviations
Study: 22749633
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy plans with no discernible justification
Study: 19188680
Drug: Low-dose bevacizumab
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose bevacizumab (7.5 mg/kg) plus cisplatin/gemcitabine
Study: 19188680
Drug: High-dose bevacizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose bevacizumab (15 mg/kg) plus cisplatin/gemcitabine
Study: 15715249
Drug: Conventional methods
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional methods (microscopic examinations of bone marrow and lymph node aspirates and immunofluorescent antibody tests)
Study: 8841868
Drug: Fentanyl 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 7.5 micrograms/kg and midazolam 0.075 mg/kg administered over 10 minutes
Study: 8841868
Drug: Fentanyl 12.5
Normalized name: FENTANYL 12.5MCG/HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 12.5 micrograms/kg and midazolam 0.125 mg/kg administered over 10 minutes
Study: 8841868
Drug: Fentanyl 20.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 20.0 micrograms/kg and midazolam 0.200 mg/kg administered over 10 minutes
Study: 8841868
Drug: Fentanyl 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 7.5 micrograms/kg and midazolam 0.075 mg/kg administered within 1 minute
Study: 1703327
Drug: Alternate chemotherapy
Normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternate chemotherapy (2 CHOP‐Bleo courses, 2 CMED courses, 2 CHOP‐Bleo courses)
Study: 7351906
Drug: High-volume fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-volume fluid intake (mean excess, 47 ml per kilogram per day)
Study: 24838406
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin D3
Study: 25350959
Drug: lersivirine 750
Normalized name: Lersivirine
DrugBank: Lersivirine (DB11649)
Approvals — FDA: no, EMA: no, PMDA: no
Description: lersivirine 750 mg qd
Study: 25350959
Drug: lersivirine 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: lersivirine 1,000 mg qd
Study: 20441724
Drug: Olanzapine (flexible-dose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (flexible-dose, mean dose 10.8 ± 5.7 mg/d)
Study: 17922461
Drug: Conventional adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional adjuvant chemotherapy
Study: 17922461
Drug: Dose-intensified adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-intensified adjuvant chemotherapy
Study: 12161491
Drug: GnRH analog
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH analog therapy
Study: 1636133
Drug: Perioperative antibiotic
Normalized name: ENSURE SURGERY PERIOPERATIVE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative antibiotic use
Study: 8366411
Drug: No antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotic
Study: 30103187
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) - up to 20 sessions
Study: 26718306
Drug: Depo-Provera (medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depo-Provera (medroxyprogesterone acetate), one injection every 3 months for 6 months (2 doses)
Study: 26718306
Drug: Oral cyclic
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclic Norethisterone acetate (NETA), 15 mg daily for 14 days per cycle for 6 months
Study: 17967583
Drug: Catheter-directed thrombolysis
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catheter-directed thrombolysis (CDT) in addition to conventional treatment
Study: 15774775
Drug: Continuous-infusion fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Continuous-infusion fluorouracil (CIFU) 250 mg/m²/d for 56 days every 9 weeks for three cycles plus levamisole 50 mg tid for 3 days every other week
Study: 15774775
Drug: Fluorouracil (FU)
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil (FU) 425 mg/m² and leucovorin (LV) 20 mg/m² daily for 5 days every 28 to 35 days for six cycles plus levamisole 50 mg tid for 3 days every other week
Study: 9810302
Drug: Anesthetic cream
Normalized name: DIBUCAINE/DIPERODON ANESTHETIC CREAM
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anesthetic cream combined with lidocaine infiltration
Study: 2142428
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (600 mg per day for three months)
Study: 22589376
Drug: CCX354-C 100
Normalized name: C-Topical 100 MG/ML Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCX354-C 100 mg twice daily
Study: 22589376
Drug: CCX354-C 200
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CCX354-C 200 mg once daily
Study: 21691341
Drug: Mindfulness group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness group (MG) training
Study: 20001979
Drug: Carvedilol (monotherapy)
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol (monotherapy)
Study: 9578521
Drug: VGB 100-150
Normalized name: VGB-R04
DrugBank: VGB-R04 (DB18615)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VGB 100-150 mg/kg/day
Study: 7526056
Drug: moexipril 3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: moexipril 3.75 mg
Study: 7526056
Drug: moexipril 7.5
Normalized name: moexipril 7.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: moexipril 7.5 mg
Study: 10376852
Drug: moexipril 15
Normalized name: moexipril 15 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: moexipril 15 mg
Study: 3317356
Drug: Yeast-derived hepatitis
Normalized name: YEAST CELL,LIVE DERIVATIVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yeast-derived hepatitis B vaccine (Engerix-B)
Study: 22731679
Drug: Polymerized type
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymerized type I collagen (PC), weekly subcutaneous intralesional injections ranging from 0.2 mL to 1.0 mL (1.66 mg to 8.3 mg collagen) for 3 months.
Study: 22731679
Drug: Methylprednisolone (MP),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (MP), monthly subcutaneous intralesional injections of 0.1 mL (20 mg/mL each month) for 3 months.
Study: 19795993
Drug: Inactive/placebo laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive/placebo laser treatment
Study: 7574508
Drug: Cefixime 200
Normalized name: cefixime 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime 200 mg orally every 12 h for 2 days (group 1, 4 h sampling)
Study: 7574508
Drug: Cefixime 200
Normalized name: cefixime 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime 200 mg orally every 12 h for 2 days (group 2, 12 h sampling)
Study: 7574508
Drug: Cefixime 200
Normalized name: cefixime 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime 200 mg orally every 12 h for 2 days
Study: 17014273
Drug: Individual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual therapy upon request
Study: 23472957
Drug: Phonological Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phonological Therapy (PT)
Study: 23472957
Drug: Articulation Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Articulation Therapy (AT)
Study: 21592370
Drug: Weekly docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly docetaxel (33 mg/m2)
Study: 21592370
Drug: 3-weekly docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-weekly docetaxel (100 mg/m2)
Study: 16721678
Drug: Total mesorectal
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total mesorectal excision (TME) with preoperative therapy
Study: 16721678
Drug: Total mesorectal
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total mesorectal excision (TME) without preoperative therapy
Study: 9391811
Drug: Epidural perineural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural perineural injections
Study: 9391811
Drug: Epidural perineural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural perineural injections with triamcinolone (10 mg)
Study: 9391811
Drug: Conventional posterior
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional posterior epidural injections
Study: 2467095
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g daily of safflower oil (linoleic acid)
Study: 29627888
Drug: High-Intensity Laser
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Intensity Laser Therapy (HILT) (1064 nm)
Study: 29627888
Drug: Low-Level Laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Level Laser Therapy (LLLT) (904 nm)
Study: 22069361
Drug: BDP/F 400/24
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP/F 400/24 μg/day
Study: 22069361
Drug: FP/S 500/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: FP/S 500/100 μg/day
Study: 16621870
Drug: Prasugrel 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 40 mg loading dose (LD) / 5 mg maintenance dose (MD)
Study: 16621870
Drug: Prasugrel 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 40 mg LD / 7.5 mg MD
Study: 18217157
Drug: Clopidogrel 300
Normalized name: clopidogrel 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 300 mg LD / 75 mg MD
Study: 24990396
Drug: Prasugrel 10
Normalized name: prasugrel 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 10 mg MD
Study: 16633079
Drug: Prasugrel 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 15 mg MD
Study: 11709686
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (neither drug)
Study: 3229867
Drug: Propranolol therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol therapy
Study: 20665472
Drug: E. laciniata
Approvals — FDA: no, EMA: no, PMDA: no
Description: E. laciniata extract ointment
Study: 11228355
Drug: Conjugate vaccine
Normalized name: meningococcal conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugate vaccine without aluminium hydroxide adjuvant
Study: 11228355
Drug: Conjugate vaccine
Normalized name: meningococcal conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugate vaccine with aluminium hydroxide adjuvant
Study: 11228355
Drug: 23-valent PS
Normalized name: Streptococcus pneumoniae type 1 capsular polysaccharide antigen
DrugBank: Streptococcus pneumoniae type 1 capsular polysaccharide antigen (DB10319)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23-valent PS vaccine (control)
Study: 11228355
Drug: Both conjugate
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both conjugate vaccines
Study: 9508168
Drug: Mitoxantrone (MTZ)
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitoxantrone (MTZ) 8 mg/m2 on days 1, 2, and 3 plus cytarabine (Ara‐C) 100 mg/m2 on days 1 to 7
Study: 9508168
Drug: Daunomycin (DNR)
Normalized name: Daunomycin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daunomycin (DNR) 30 mg/m2 on days 1, 2, and 3 plus cytarabine (Ara‐C) 100 mg/m2 on days 1 to 7
Study: 9508168
Drug: Low-dose cytarabine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cytarabine (LD-Ara-C) 10 mg/m2 subcutaneously every 12 hours for 12 days every 6 weeks
Study: 9508168
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further treatment after initial chemotherapy
Study: 9508168
Drug: Low-dose cytarabine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cytarabine (LD-Ara-C)
Study: 8310991
Drug: Psyllium seed
Normalized name: Psyllium seed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium seed (10 g/d for 3 weeks)
Study: 8310991
Drug: Psyllium husk
Normalized name: Psyllium Husk
DrugBank: Plantago seed (DB11097)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium husk (10 g/d for 3 weeks)
Study: 26677669
Drug: Ziyin Huoxue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziyin Huoxue Granule (ZHG) combined with glucocorticoids and antibiotics
Study: 26677669
Drug: Glucocorticoids and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoids and antibiotics alone (Control)
Study: 17164738
Drug: Subcutaneous preoperative
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous preoperative reviparin (4,200 anti Xa IU) once daily
Study: 17164738
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (7,500 IU) twice daily
Study: 10712343
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate (FP) at 880 microg
Study: 1323926
Drug: Soy phosphatidylcholine
Normalized name: hydrogenated soy phosphatidylcholine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy phosphatidylcholine (PC) 27 g
Study: 1323926
Drug: Soy phosphatidylcholine
Normalized name: hydrogenated soy phosphatidylcholine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy phosphatidylcholine (PC) 18 g
Study: 6507905
Drug: Intravenous bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bupivacaine (2 mg/min for 3 hr)
Study: 21035214
Drug: Upstream GP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upstream GP IIb/IIIa inhibitors therapy
Study: 20939113
Drug: STRD (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: STRD (100 mg of hydrocortisone before PM and on postoperative days 1, 2, 3)
Study: 18522627
Drug: CS-706 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS-706 (50 mg oral dose)
Study: 10372241
Drug: KJM fiber-enriched
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KJM fiber-enriched test biscuits (0.7 g/412 kJ [100 kcal] of glucomannan)
Study: 29663901
Drug: Community-led surveillance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-led surveillance and treatment in intervention villages (5 villages, 997 residents)
Study: 24154863
Drug: Standard-dose prasugrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose prasugrel (60 mg loading dose / 10 mg daily maintenance dose)
Study: 24154863
Drug: Standard-dose prasugrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose prasugrel (10 mg daily maintenance dose)